Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Langsenlehner, T; Renner, W; Gerger, A; Hofmann, G; Thurner, EM; Kapp, KS; Langsenlehner, U.
Association between single nucleotide polymorphisms in the gene for XRCC1 and radiation-induced late toxicity in prostate cancer patients.
Radiother Oncol. 2011; 98(3):387-393
Doi: 10.1016/j.radonc.2011.01.021
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Langsenlehner Tanja
- Co-Autor*innen der Med Uni Graz
- Gerger Armin
- Hofmann Guenter
- Kapp Karin S.
- Langsenlehner Uwe
- Renner Wilfried
- Thurner Eva-Maria
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Polymorphisms in genes responsible for DNA damage signaling and repair might modulate DNA repair capacity and, therefore, affect cell and tissue response to radiation and influence individual radiosensitivity. The purpose of the present prospective investigation was to evaluate the association of single nucleotide polymorphisms in XRCC1 with radiation-induced late side effects in prostate cancer patients treated with radiotherapy. To analyze the role of XRCC1 polymorphisms for late toxicity 603 participants from the Austrian PROCAGENE study treated with three-dimensional conformal radiotherapy were included in the present investigation. Three non-synonymous candidate polymorphisms in the X-ray repair cross-complementing group 1 (XRCC1) gene (Arg194Trp; Arg280His; Arg399Gln) were selected and determined by 5´-nuclease (TaqMan) assays. Within a median follow-up time of 35 months, 91 patients (15.7%) developed high-grade late toxicities (defined as late bladder and/or rectal toxicity RTOG≥2). In a Kaplan-Meier analysis, carriers of the XRCC1 Arg280His polymorphism were at decreased risk of high-grade late toxicity (p=0.022), in multivariate analysis including clinical and dosimetric parameters as potential confounders the XRCC1 Arg280His polymorphism remained a significant predictor for high-grade late toxicity (HR=0.221, 95% CI 0.051-0.956; p=0.043). No significant associations were found for the remaining polymorphisms. We conclude that the XRCC1 Arg280His polymorphism may be protective against the development of high-grade late toxicity after radiotherapy in prostate cancer patients. Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Austria -
- DNA-Binding Proteins - genetics
- Humans -
- Male -
- Polymorphism, Single Nucleotide -
- Prostatic Neoplasms - genetics
- Prostatic Neoplasms - radiotherapy
- Radiation Tolerance - genetics
- Radiotherapy, Conformal - adverse effects
- Rectum - radiation effects
- Time Factors -
- Urinary Bladder - radiation effects
- X-ray Repair Cross Complementing Protein 1 -
- Find related publications in this database (Keywords)
- Radiotherapy
- Late toxicity
- Predictive factors
- DNA repair
- XRCC1 polymorphisms